Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The management of early stage hepatocellular carcinoma (HCC) presents significant challenges. While radiofrequency ablation (RFA) has shown safety and effectiveness in treating HCC, with lower mortality rates and shorter hospital stays, its high recurrence rate remains a significant impediment. Consequently, achieving improved survival solely through RFA is challenging, particularly in retrospective studies with inherent biases. Ultrasound is commonly used for guiding percutaneous RFA, but its low contrast can lead to missed tumors and the risk of HCC recurrence. To enhance the efficiency of ultrasound-guided percutaneous RFA, various techniques such as artificial ascites and contrast-enhanced ultrasound have been developed to facilitate complete tumor ablation. Minimally invasive surgery (MIS) offers advantages over open surgery and has gained traction in various surgical fields. Recent studies suggest that laparoscopic intraoperative RFA (IORFA) may be more effective than percutaneous RFA in terms of survival for HCC patients unsuitable for surgery, highlighting its significance. Therefore, combining MIS-IORFA with these enhanced percutaneous RFA techniques may hold greater significance for HCC treatment using the MIS-IORFA approach. This article reviews liver resection and RFA in HCC treatment, comparing their merits and proposing a trajectory involving their combination in future therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622093PMC
http://dx.doi.org/10.4240/wjgs.v16.i11.3400DOI Listing

Publication Analysis

Top Keywords

percutaneous rfa
16
radiofrequency ablation
8
minimally invasive
8
invasive surgery
8
hepatocellular carcinoma
8
rfa
8
rfa techniques
8
hcc treatment
8
hcc
6
percutaneous
5

Similar Publications

Objective: To assess the efficacy and safety of ultrasound-guided electrocoagulation for pathological perforating veins in advanced lower extremity chronic venous insufficiency.

Methods: This study enrolled 455 patients (497 affected limbs) with venous insufficiency. Pathological perforating veins (diameter ≥3.

View Article and Find Full Text PDF

This study aimed to evaluate the efficacy and safety of percutaneous microwave ablation (MWA) versus radiofrequency ablation (RFA) for the treatment of pulmonary metastasis. A systematic literature search was conducted using the PubMed, Embase, and Cochrane Library databases from their inception through October 2023. Studies comparing MWA and RFA for pulmonary metastasis were included.

View Article and Find Full Text PDF

Background & Aims: We aimed to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).

Methods: We prospectively included patients with a first diagnosis of HCC who underwent tumor and non-tumor biopsies during percutaneous RFA between 2015 and 2021. We analyzed the complications, percentage of diagnostic tumor biopsies, ability to perform molecular biology, and the non-tumor liver biopsy results, and correlated histology with prior non-invasive diagnosis and oncological outcomes.

View Article and Find Full Text PDF

Background: Percutaneous radiofrequency ablation (RFA) is a commonly used treatment for inoperable early-stage lung cancer, though it carries a significant risk of complications. Transbronchial RFA has emerged as a promising alternative, but robust clinical evidence supporting its adoption remains scarce. This study aims to investigate the safety and efficacy of transbronchial RFA in treating early-stage peripheral lung cancer.

View Article and Find Full Text PDF

Aims: To assess the viability and safety of radiofrequency ablation (RFA) for intrahepatic tumors in hepatocellular carcinoma (HCC) treatment, as well as percutaneous ethanol injection (PEI) for portal vein tumor thrombus (PVTT).

Materials And Methods: From January 2010 to December 2020, a total of 25 HCC patients who underwent RFA for intrahepatic tumor combined with PEI for PVTT were enrolled. Treatment response (assessed using modified Response Evaluation Criteria in Solid Tumors [mRECIST] based on contrast-enhanced computed tomography [CECT] or contrast-enhanced ultrasound [CEUS]), overall survival (OS), progression-free survival (PFS), and safety profile were evaluated.

View Article and Find Full Text PDF